In Utero SARS-CoV-2 Exposure Tied to Neurodevelopmental Sequelae

FRIDAY, June 10, 2022 (HealthDay News) -- In utero exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with increased neurodevelopmental sequelae in offspring, according to a study published online June 9 in JAMA Network Open.
Andrea G. Edlow, M.D., from Massachusetts General Hospital in Boston, and colleagues examined whether in utero exposure to SARS-CoV-2 is associated with risk for neurodevelopmental disorders in the first 12 months in a retrospective cohort study of live offspring of mothers who delivered between March and September 2020. Data were included for 7,772 live births.
The researchers found that exposed mothers were more likely to have preterm delivery (14.4 versus 8.7 percent). In unadjusted models, the rate of neurodevelopmental diagnoses was increased with maternal SARS-CoV-2 positivity during pregnancy (odds ratio, 2.17), as well as in analyses adjusted for race, ethnicity, insurance status, offspring sex, maternal age, and preterm status (adjusted odds ratio, 1.86). Effects of larger magnitude were seen in association with third-trimester infection (adjusted odds ratio, 2.34).
"These preliminary findings suggest greater risk for adverse neurodevelopmental outcomes at 1 year among offspring exposed to SARS-CoV-2, and highlight the urgency of follow-up studies in large and representative cohorts," the authors write.
Several authors disclosed financial ties to the biopharmaceutical industry.
Related Posts
Enforcing BMI Cutoffs for Shoulder Joint Surgery Could Exacerbate Disparities
WEDNESDAY, Aug. 2, 2023 (HealthDay News) -- Enforcing body mass index (BMI)...
Americans Turning to Trendy Diets to Shed Pandemic Pounds
MONDAY, Dec. 20, 2021 (HealthDay News) -- Americans in the prime of their lives...
Blood Donors’ Gender Doesn’t Affect Outcomes for Recipients
THURSDAY, April 13, 2023 (HealthDay News) -- Whether the gender of a blood donor...
T-Cell Redirection Therapy Studied for Relapsed Multiple Myeloma
THURSDAY, Sept. 15, 2022 (HealthDay News) -- In patients with heavily pretreated...